S

Shenzhen Salubris Pharmaceuticals Co Ltd
SZSE:002294

Watchlist Manager
Shenzhen Salubris Pharmaceuticals Co Ltd
SZSE:002294
Watchlist
Price: 31.73 CNY -3.99% Market Closed
Market Cap: 35.4B CNY
Have any thoughts about
Shenzhen Salubris Pharmaceuticals Co Ltd?
Write Note

Shenzhen Salubris Pharmaceuticals Co Ltd
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Shenzhen Salubris Pharmaceuticals Co Ltd
Cash from Financing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
S
Shenzhen Salubris Pharmaceuticals Co Ltd
SZSE:002294
Cash from Financing Activities
-ÂĄ92.9m
CAGR 3-Years
N/A
CAGR 5-Years
32%
CAGR 10-Years
13%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Cash from Financing Activities
-ÂĄ753.7m
CAGR 3-Years
10%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Cash from Financing Activities
-ÂĄ2.1B
CAGR 3-Years
-52%
CAGR 5-Years
-54%
CAGR 10-Years
N/A
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Cash from Financing Activities
-ÂĄ1.6B
CAGR 3-Years
-84%
CAGR 5-Years
-15%
CAGR 10-Years
-105%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Cash from Financing Activities
-ÂĄ3B
CAGR 3-Years
15%
CAGR 5-Years
20%
CAGR 10-Years
-19%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Cash from Financing Activities
ÂĄ90.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Shenzhen Salubris Pharmaceuticals Co Ltd
Glance View

Market Cap
34.6B CNY
Industry
Pharmaceuticals

Shenzhen Salubris Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of pharmaceuticals and medical devices. The company is headquartered in Shenzhen, Guangdong and currently employs 3,236 full-time employees. The company went IPO on 2009-09-10. The firm provides two categories of products: pharmaceutical preparation and bulk drugs. The firm is also engaged in the research and development, production and sales of cardiovascular medical devices. The firm distributes its products within domestic market and to overseas markets.

Intrinsic Value
25.15 CNY
Overvaluation 21%
Intrinsic Value
Price
S

See Also

What is Shenzhen Salubris Pharmaceuticals Co Ltd's Cash from Financing Activities?
Cash from Financing Activities
-92.9m CNY

Based on the financial report for Sep 30, 2024, Shenzhen Salubris Pharmaceuticals Co Ltd's Cash from Financing Activities amounts to -92.9m CNY.

What is Shenzhen Salubris Pharmaceuticals Co Ltd's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
13%

Over the last year, the Cash from Financing Activities growth was 82%.

Back to Top